
Opinion|Videos|December 10, 2024
Vowst as a Potential Option for Patients With Recurrent C Difficile Infections
Author(s)Paul Feuerstadt, MD, FACG, AGAF
The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut bacteria to restore microbiome diversity, distinguishing itself from traditional antibiotics in preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment.
Advertisement
Video content above is prompted by the following:
- What is the mechanism of action of Vowst, and how does this therapy differ from previously used therapies in recurrent C difficile infections?
- What is the key data that led to the FDA-approval of Vowst for recurrent C difficile infection?
- Who are the target patient populations for Vowst?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review
2
US, Japan Patients With Diabetes Discontinue Semaglutide After First Year
3
Teclistamab for R/R MM Effective and Safe When Administered in a Community Setting
4
Contributor: Medication Adherence as a Journey—A Year-Round Strategy for Medicare Advantage Success
5